Test Price
2,800 AEDโ Home Collection Available
MYO3A Gene Deafness, Autosomal Recessive Type 30, Genetic Test in UAE โ NGS Sequencing
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO 9001:2015 certified processing (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (available daily from 8 AM to 11 PM).
- Clinical Guidance: Post-test telephonic guidance in result interpretation by DHA-licensed genetic counsellors.
- Insurance: Direct billing verification via WhatsApp: +971 54 548 8731.
Test Overview & Methodology
This advanced Next-Generation Sequencing (NGS) test analyses the entire coding region of the MYO3A gene to identify pathogenic variants responsible for autosomal recessive deafness type 30. Tailored for UAE families, it delivers a definitive molecular diagnosis that informs early intervention and genetic counselling.
| Feature | Our NGS Test (Premium) | Standard Sanger Sequencing |
|---|---|---|
| Methodology | High-throughput NGS โ full gene coverage | Targeted exon-by-exon read |
| Sensitivity | 99.9% for all variant types (SNVs, InDels) | ~90%; misses large rearrangements |
| Turnaround Time | 3โ4 weeks | 4โ6 weeks |
| Regulatory Recognition | DHA/MOHAP Standards, ISO 9001:2015 | Limited laboratory-specific validation |
All comparisons are based on current UAE clinical laboratory benchmarks.
Physician Insight & Safety Protocols
โWhile the MYO3A NGS panel provides exceptional diagnostic clarity, a thorough audiometric evaluation and detailed family history remain indispensable. We advocate pre- and post-test genetic counselling to ensure that every patient fully understands the implications for themselves and their relatives.โ โ Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA Registration ID: 9294403
Advisory: Medication Continuation
Do not discontinue any prescribed medication without consulting your doctor. Inform the phlebotomist about all current medications before sample collection.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Known severe bleeding disorders (e.g., haemophilia, platelet count <50ร10โน/L) unless cleared by haematologist.
- Exclusion: Active infection or cellulitis at the planned venipuncture site.
- Exclusion: Minors without a legal guardian present.
- Exclusion: Uncontrolled vasovagal syncope; must be disclosed before sampling.
- ER Red Flags: Immediately seek emergency care if you experience expanding haematoma, persistent bleeding >15 min, dizziness, shortness of breath, or signs of infection (redness, pus) after sample collection.
Patient FAQ & Clinical Guidance
1. What is the MYO3A gene test and why is it performed?
The MYO3A Genetic Test sequences the entire MYO3A gene to detect pathogenic variants causing autosomal recessive deafness type 30, enabling precise diagnosis and hereditary risk assessment. It is recommended when clinical audiometry suggests a genetic form of hearing loss, especially with a positive family history.
2. What sample is required and how is home collection arranged?
A healthcare professional collects a small blood sample via painless venipuncture at your home from 8 AM to 11 PM; dried blood spot on FTA card is also an option. Simply WhatsApp +971 54 548 8731 to schedule VIP mobile phlebotomy, and you will receive pre-test guidance and a consent form by email.
3. How long until I receive my results and what does the 2800 AED fee include?
Results are delivered within 3โ4 weeks in a comprehensive report; the 2800 AED fee covers genetic counselling session, home collection, laboratory analysis, and post-test phone consultation. You will also receive a digital copy via our secure patient portal for easy sharing with your ENT specialist or geneticist.
UAE Regulatory & Data Privacy Adherence
This test is performed in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All patient data are encrypted and processed within secure UAE infrastructure. Clinical safety and patient consent follow Federal Decree-Law No. 4 of 2016 on Medical Liability.
Clinical & Logistical Metadata
| Test Name | MYO3A Gene Deafness, Autosomal Recessive Type 30, NGS Sequencing |
| Price (AED) | 2,800 |
| Turnaround Time | 3โ4 weeks |
| Sample Type / Matrix | Peripheral whole blood (EDTA) or dried blood spot (FTA card) |
| Methodology Used | Next-Generation Sequencing (NGS) โ full coding region and splice sites |
| ICD-10-CM Code | H90.5 |
| LOINC Code | 78582-0 |
| DHA Facility License & Laboratory Address | License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE โ DNA Labs UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians